profit from every €100 of sales.
€0€100
Financière de Tubize SA
€246.00+2.50% today
+17.4% since Dec 18, 25
1-year low €169.301-year high €247.50
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
You pay €117.46 for every €1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Financière de Tubize SA sold, what it kept, and what it did with the cash.
Sales went from €0 in 2022 to €0 in 2025, with €93.2 million of profit last year.
SalesProfit
Financière de Tubize SA vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| Financière de Tubize SA | 117.5× · No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Financière de Tubize SA's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| -2 | -2 | -2 | -3 | |
| -2 | -2 | -2 | -3 | |
| 87 | 90 | 93 | 94 | |
| 85 | 88 | 90 | 93 | |
| 1.91 | 1.98 | 2.02 | 2.09 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,839 | 1,920 | 1,930 | 1,934 |
| Cash | 1 | 1 | 1 | 0 |
| Total debt | 48 | 79 | 41 | 0 |
| Total liabilities | 87 | 124 | 89 | 49 |
| 1,752 | 1,797 | 1,840 | 1,886 | |
| 45 | 45 | 45 | – | |
| 3.8% | 3.8% | 3.9% | 3.9% | |
| 4.9% | 4.9% | 4.9% | 4.9% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| – | – | – | – | |
| – | – | – | – | |
| -2 | -2 | -2 | -3 | |
| Dividends paid | 33 | 38 | 43 | 46 |
| 0 | 0 | – | – | |
| – | – | – | – |
Valuation
- 117.5×
- –
- 41.13
- 5.6×
- –
- –
- –
- -0.0%
- 0.9%
- –
Profitability
- –
- –
- –
- –
- 3.7%
- 3.7%
- –
- –
- –
- –
Growth
- –
- +2.9%
- –
- –
- +0.0%
Financial health
- -0.0×
- 0.00
- –
- 130.7×
- 0.03
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 45%of 948
Bottom 6%of 560
Bottom 41%of 985
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
35No pass
Benjamin Graham
30No pass
Philip Fisher
20No pass
Peter Lynch
17No pass
Joel Greenblatt
1No pass
Charlie Munger
30No pass
Terry Smith
21No pass
Questions about Financière de Tubize SA
Is Financière de Tubize SA a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Financière de Tubize SA AI analysis
What does Financière de Tubize SA do?
Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. It is in Biotechnology, based in Brussels, Belgium.
Does Financière de Tubize SA pay a dividend?
Yes. In 2025 it paid out €46.3 million in dividends.
Is Financière de Tubize SA stock halal?
Yes. Financière de Tubize SA passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
Who are Financière de Tubize SA's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Financière de Tubize SA's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.